Business
Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results
RAHWAY, N.J., October 30, 2025--Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results
About this update from Merck & Company, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":217,"url":"https://media.zenfs.com/en/business-wire.com/c36d27ad3ddbdcc0de3c2d2636159381"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vMMMa_zVkynnvQbwBr6kUw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQzNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/c36d27ad3ddbdcc0de3c2d2636159381","width":480,"height":217}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Total Worldwide Sales Were $17.3 Billion, an Increase of 4% From Third Quarter 2024; Excluding the Impact of Foreign Exchange, Sales Grew 3%","length":140,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"KEYTRUDA Sales Grew 10% to $8.1 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 8%","length":96,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"WINREVAIR Sales Were $360 Million; Growth of 141% Both Nominally and Excluding the Impact of Foreign Exchange","length":109,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"CAPVAXIVE Sales Were $244 Million","length":33,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"GARDASIL/GARDASIL 9 Sales Declined 24% to $1.7 Billion; Excluding the Impact of Foreign Exchange, Sales Declined 25%","length":116,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Animal Health Sales Grew 9% to $1.6 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 7%","length":100,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":454,"olType":false}]},{"val":[{"type":"text","content":"GAAP EPS Was $2.32; Non-GAAP EPS Was $2.58; GAAP and Non-GAAP EPS Include a Charge of $0.10 per Share for Milestone Payment to LaNova for Technology Transfer for MK-2010","length":169,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Received FDA Approval of KEYTRUDA QLEX Injection for Subcutaneous Use Across All Solid Tumor Indications for KEYTRUDA","length":117,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Presented New Research Across More Than 20 Types of Cancer and Multiple Treatment Settings at ESMO Congress 2025, Including Positive Survival Data From KEYNOTE-905 and KEYNOTE-B96","length":179,"tagName":"p","attribs":{}}]},{"val":[{...